Trends in Biotechnology
ReviewSpecial Issue: Celebrating 30 years of biotechnologyCombination approaches to combat multidrug-resistant bacteria
Highlights
► Combination approaches to combat multidrug-resistant bacteria. ► The problem of drug-resistant bacterial infections continues to worsen. ► Bacteria will inevitably acquire resistance against new antibiotics. ► Antibiotic–adjuvant combinations are an attractive approach to treat infections.
Section snippets
The problem of multidrug-resistant bacteria
The emergence of resistance to multiple antimicrobial agents in pathogenic bacteria has become a significant global public health threat. Drug-resistant bacterial infections cause considerable patient mortality and morbidity, and rising antibiotic resistance is seriously threatening the vast medical advancements made possible by antibiotics over the past 70 years [1]. For example, in 2005 almost 95 000 people acquired methicillin-resistant Staphylococcus aureus (MRSA) infections in the United
Combinations of two or more antibiotics
One approach to combating MDR infections is combination of two or more antimicrobial drugs during a treatment regimen. Although the possibility of drug–drug interactions is a possible pitfall to this approach, and must be taken into consideration during the drug development process, combination therapy is common and critical in many areas of medicine. For example, drug combinations are key to most cancer treatments [9]. Combination therapy regimens have long been used to treat HIV-infected
Antibiotic/adjuvant combinations
An alternative to the combination of two or more drugs with known antibiotic activity for the treatment of MDR bacterial infections is to combine an antibiotic with a compound that is not, when administered alone, microbicidal but increases the activity of the antibiotic, for example, by blocking the mechanism of resistance to the antibiotic. Such an approach is particularly attractive because it may also result in a decrease in the onset of resistance development. Antibiotic resistance
Screening of previously approved drugs
The redeployment of drugs that have previously been approved for other indications is an attractive approach to the discovery of antibiotic adjuvants because these drugs have known toxicology and pharmacology profiles. It is estimated that by taking this approach, the overall cost of bringing a drug to market can be reduced by almost 40%, as a result of elimination of much of the toxicological and pharmacokinetic assessment required for drug approval [48]. Systematic screening of approved
Concluding remarks
With the continuing rise in occurrence of drug-resistant strains of bacteria, new approaches to combating infections caused by these bacteria are urgently needed, particularly for Gram-negative bacteria. The one drug–one target model has limited viability, and combination therapy is the norm in the treatment of many cancers, viral infections such as HIV, and tuberculosis. The use of combination therapy, or other drug cocktails such as antibiotic/adjuvant combinations for the treatment of other
Acknowledgments
We would like to thank the NIH (R01GM055769 and R21AI096015), the V foundation, and the DOD DMRDP program (W81XWH-11-2-0115) for their support. The DMRDP program is administered by the Department of Army; the US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014 is the awarding and administering office. The content of this manuscript does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.
References (62)
Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies
Clin. Microbiol. Infect.
(2008)Combination therapies for combating antimicrobial resistance
Curr. Opin. Microbiol.
(2011)- et al.
Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology
Clin. Microbiol. Infect.
(2006) - et al.
Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria
Biochim. Biophys. Acta
(2009) - et al.
Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use
Biochem. Pharmacol.
(2006) Two-component signal transduction as potential drug targets in pathogenic bacteria
Curr. Opin. Microbiol.
(2010)- et al.
Histidine kinases as targets for new antimicrobial agents
Bioorg. Med. Chem.
(2002) - et al.
Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections
Int. J. Antimicrob. Agents
(2012) Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis
Int. J. Antimicrob. Agents
(2000)Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!
Int. J. Antimicrob. Agents
(2010)
Promethazine renders Escherichia coli susceptible to penicillin G: real-time measurement of bacterial susceptibility by fluoro-luminometry
Int. J. Antimicrob. Agents
Microbiology. Desperately seeking new antibiotics
Science
Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005
Emerg. Infect. Dis.
Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development
Infection
New treatment options against gram-negative organisms
Crit. Care
The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America
Clin. Infect. Dis.
Where are all the new antibiotics? The new antibiotic paradox
Can. J. Infect. Dis. Med. Microbiol.
Molecular mechanisms that confer antibacterial drug resistance
Nature
Sequencing of superbugs seen as key to combating their spread
Nat. Med.
Designer combination therapy for cancer
Nat. Biotechnol.
HIV chemotherapy
Nature
Artemisinin-based combination treatment of falciparum malaria
Am. J. Trop. Med. Hyg.
The chemotherapy of tuberculosis: past, present and future
Int. J. Tuberc. Lung Dis.
Combination therapy for treatment of infections with gram-negative bacteria
Clin. Microbiol. Rev.
Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus
ACS Chem. Biol.
Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to beta-lactams
ACS Chem. Biol.
Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics
J. Antimicrob. Chemother.
The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections
Int. J. Antimicrob. Agents
Where will new antibiotics come from?
Nat. Rev. Microbiol.
Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?
J. Antimicrob. Chemother.
Efficacy of piperacillin combined with the penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection
Antimicrob. Agents Chemother.
Cited by (474)
Proguanil and chlorhexidine augment the antibacterial activities of clarithromycin and rifampicin against Acinetobacter baumannii
2024, International Journal of Antimicrobial AgentsAdaptive evolution in asymptomatic host confers MDR Salmonella with enhanced environmental persistence and virulence
2024, Science of the Total EnvironmentAnti bacterial function of secreted human FABP3
2023, Biochimica et Biophysica Acta - General SubjectsInfluence of konjac glucomannan and its derivatives on the oral pharmacokinetics of antimicrobial agent in antibiotics cocktails: Keep vigilant on dietary fiber supplement
2023, International Journal of Biological Macromolecules